Some people, frustratingly, don’t lose as much weight as others on popular weight-loss drugs like Wegovy. A new study suggests the answer may be in their genes. 🔗 https://t.co/9mIQLUfNmO https://t.co/Xj54ahGSMQ ...

Until now, revolutionary weight-loss drugs have been available largely to people with means. @julianaliu writes that affordable generics will be a leveling force in healthcare (via @opinion) https://t.co/U1T6DYdoRU ...

In today’s India Edition, Menaka Doshi looks at the slowdown on deal street, and Satviki Sanjay counts down to cheaper weight-loss drugs in the country. https://t.co/UnpPiY2BQv ...

Core Insights - The weight-loss drug market is rapidly growing, with investment opportunities in established companies like Eli Lilly and Novo Nordisk, as well as smaller biotech firms like Viking Therapeutics [1][2] Company Overview - Viking Therapeutics is focusing on developing VK2735, a GLP-1 medicine currently in phase 3 clinical trials, which increases the likelihood of approval compared to candidates in earlier stages [5][10] - The company is exploring both subcutaneous and oral formulations of VK2735, aiming to address the challenge of maintaining weight loss after treatment [7][8] Market Potential - As of mid-2025, there are 277 obesity-drug candidates in development, but most are unlikely to receive approval, highlighting the competitive nature of the market [4] - Viking's strong mid-stage results for VK2735 position it favorably within this competitive landscape, potentially leading to significant financial success and stock market returns over the next decade [8] Investment Considerations - Investing in Viking Therapeutics is considered riskier but may offer higher upside potential, with a suggested investment of $5,000 for those with above-average risk tolerance [2][10] - The success of VK2735 in phase 3 trials is critical for the company's future market impact and stock performance [10]

Core Insights - Eli Lilly has built a pre-launch inventory of its experimental oral weight-loss drug, orforglipron, valued at $1.5 billion ahead of an expected FDA decision in April [1] - This inventory has increased significantly from nearly $550 million reported last year, indicating strong preparation for a potential launch [1] - The company aims to have sufficient supply to launch the drug in multiple countries simultaneously if it receives U.S. approval [1] Company Developments - Eli Lilly's orforglipron has received a fast-track review voucher from the FDA, potentially reducing the review time to one to two months compared to the typical 10 to 12 months for new medicines [1] - The competitive landscape includes Danish rival Novo Nordisk, which recently launched its own weight-loss pill in the U.S., achieving over 26,000 prescriptions in the second week post-launch [1] Financial Implications - The pre-launch inventory is a strategic asset that reflects Eli Lilly's confidence in the drug's approval and market potential [1] - Such inventories are commonly included in financial statements to demonstrate the readiness of drug products prior to regulatory approval [1]

Nam, could you just tell us about the shift that's taking place right now in the global market for for weight loss drugs. >> So, I mean, we're we're going really from a few years where Novon Nordisk couldn't make enough semiglutide to supply the market um in the US, let alone in the rest of the world. um to a time when um in a growing number of countries there will be a lot of generic competitors on the market and people will suddenly have access that they never had before to super powerful obesity medicine ...

Core Viewpoint - Eli Lilly & Co. has provided a positive sales forecast for the year, driven by strong demand for its weight loss drug, positioning it favorably in the obesity market compared to rival Novo Nordisk, which anticipates a sales decline due to price competition [1][3]. Sales Forecast and Market Position - Lilly expects full-year sales to reach between $80 billion and $83 billion, surpassing Wall Street's average estimate of $77.7 billion [3] - The company anticipates a sales growth of up to 27% this year, contrasting with Novo Nordisk's warning of a potential 13% sales drop [1][3]. Competitive Landscape - Lilly's Mounjaro and Zepbound drugs have a decade of patent life remaining, giving it a competitive edge over Novo, whose drugs may face generic competition soon [3] - Lilly's Zepbound has shown to be more effective than Novo's Wegovy, with patients losing about two inches more off their waists in head-to-head studies [10]. Product Developments - Lilly is preparing to launch a new multidose version of Zepbound, which will be available for Medicare patients once coverage is established [7][8]. - The company is also awaiting approval for its weight loss pill, expected as soon as April, with a projected cost of $149 per month for the lowest dose [6][5]. Financial Performance - In the fourth quarter, Lilly reported sales of $19.3 billion, exceeding analyst estimates of $18 billion, with Zepbound sales at $4.3 billion and Mounjaro at $7.4 billion [15]. - Lilly's earnings per share of $7.54 also surpassed expectations of $6.73 [15]. Future Prospects - Lilly is testing new weight-loss drugs, including retatrutide, which has shown promising results in trials, potentially making it the most effective weight-loss medicine [12]. - The company is expanding its research into other therapeutic areas, including neuroscience and cancer, with new drugs like Kisunla for Alzheimer's [14].

Core Viewpoint - Eli Lilly forecasts 2026 profit exceeding Wall Street estimates due to strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro, which are expected to counteract pricing pressures in the U.S. market [1] Group 1 - Eli Lilly anticipates robust demand for its blockbuster drugs, Zepbound and Mounjaro, contributing to profit growth [1] - The company expects to overcome pricing pressures in its largest market, the U.S., through the success of these drugs [1]

Restaurant chains are pumping protein into everything from pizza crust to coffee, while stepping up marketing to users of weight-loss drugs and fitness buffs https://t.co/XIJcBbPmLA ...

Popular weight-loss drugs are meant to be lifelong medications treating a disease, not lifestyle fixes. https://t.co/POIwSSrK05 ...